Exploring opportunities in areas where Novartis has active efforts, such as breast and lung cancers, melanoma, renal cell carcinoma, and malignant hematology; and we seek to expand into other high-unmet need areas such as hepatocellular, pancreatic, colorectal, and prostate cancers and others. Our partnering teams are organized by stage of development (clinical stage or early), tumour type, or biology of the intervention.
Breast and Gynaecological (Ovarian, Endometrial).
Lung and Melanoma.
Solid Tumours GI/GU.
Seeking partners to significantly improve standard of care and cure patients in selected high unmet need in benign hematology diseases. The vision is to transform a number of disease specific classes not limited to hemophilia, complement disorders, anemia, sickle cell disease and thalassemia.
Leukaemias and Myeloid Dysplastic Syndromes.
Lymphomas and Multiple myelomas, CAR-T programs.